Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Novo Nordisk proposes Ablynx takeover for cash bid of €28/share, CVRs; later outbid by Sanofi

Executive Summary

Ablynx NV first announced to the public offers made back in December 2017 by fellow antibody developer Novo Nordisk AS, which initially proposed on December 6th to acquire Ablynx for €26.75 ($31.60; a 39% premium) per share (for an equity value of €1.99bn); the Ablynx board rejected the offer, claiming it undervalued the company. In a revised bid on December 22nd, Novo offered €28.00 per share (a 46% premium) in cash, plus up to €2.50/share in contingent value rights (CVRs; based on the progress of two Ablynx development candidates), for an equity value of €2.3bn ($2.7bn), which Ablynx also vetoed. Industry sources believe a bidding war could ensue with Novo coming back with a higher offer and Gilead, Amgen, and AbbVie also joining the mix as possible suitors.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Earnout
    • Intra-Biotech Deal
    • Payment Includes Cash

Related Companies